Sanofi proposes to cease negative statements about CSL's flu vaccine amid EU probe

Sanofi has offered to stop making disparaging comments about CSL's flu vaccine following an investigation launched by the European Commission. The offer comes two weeks after the Commission began probing Sanofi's claims about the rival product.

The dispute centers on Sanofi's enhanced flu vaccine, which it had criticized as inferior to CSL's offering. By agreeing to end the negative statements, Sanofi aims to resolve the regulatory scrutiny.

The development may ease tensions between the two companies and could influence ongoing regulatory assessments of flu vaccines in Europe.